4D Molecular Therapeutics, Inc. Operating Lease Cost
4D Molecular Therapeutics, Inc. (FDMT) reported Operating Lease Cost of $1.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.34M, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.34M, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.34M, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.34M, a 40.63% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, cost for fiscal 2025 was $5.38M, a 45.43% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. operating lease, cost for fiscal 2024 was $3.70M, a 32.33% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. operating lease, cost for fiscal 2023 was $2.79M, a 0.22% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. operating lease, cost for fiscal 2022 was $2.79M, a 5.93% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-13 | $2.69M 10-Q · filed 2026-08-13 | $4.03M derived: sum of 3 quarters · filed 2026-08-13 | $5.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.34M 10-Q · filed 2026-05-07 | $2.69M derived: sum of 2 quarters · filed 2026-05-07 | $4.03M derived: sum of 3 quarters · filed 2026-05-07 | $5.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.69M derived: sum of 2 quarters · filed 2026-03-18 | $4.03M derived: sum of 3 quarters · filed 2026-08-13 | $5.38M 10-K · filed 2026-03-18 |
| 2025-09-30 | $1.34M 10-Q · filed 2025-11-10 | $2.69M derived: sum of 2 quarters · filed 2026-08-13 | $4.03M 10-Q · filed 2025-11-10 | $5.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.34M 10-Q · filed 2026-08-13 | $2.69M 10-Q · filed 2026-08-13 | $4.03M derived: sum of 3 quarters · filed 2026-08-13 | $4.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.34M 10-Q · filed 2026-05-07 | $2.69M derived: sum of 2 quarters · filed 2026-05-07 | $3.64M derived: sum of 3 quarters · filed 2026-05-07 | $4.34M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.30M derived: sum of 2 quarters · filed 2026-03-18 | $3.00M derived: sum of 3 quarters · filed 2026-03-18 | $3.70M 10-K · filed 2026-03-18 |
| 2024-09-30 | $955.00K 10-Q · filed 2025-11-10 | $1.65M derived: sum of 2 quarters · filed 2025-11-10 | $2.35M 10-Q · filed 2025-11-10 | $3.05M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $698.00K 10-Q · filed 2025-08-11 | $1.40M 10-Q · filed 2025-08-11 | $2.09M derived: sum of 3 quarters · filed 2025-08-11 | $2.79M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $698.00K 10-Q · filed 2025-05-08 | $1.40M derived: sum of 2 quarters · filed 2025-05-08 | $2.09M derived: sum of 3 quarters · filed 2025-05-08 | $2.79M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $698.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.40M derived: sum of 2 quarters · filed 2025-02-28 | $2.09M derived: sum of 3 quarters · filed 2025-02-28 | $2.79M 10-K · filed 2025-02-28 |
| 2023-09-30 | $698.00K 10-Q · filed 2024-11-13 | $1.40M derived: sum of 2 quarters · filed 2024-11-13 | $2.10M 10-Q · filed 2024-11-13 | $2.79M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $698.00K 10-Q · filed 2024-08-08 | $1.40M 10-Q · filed 2024-08-08 | $2.09M derived: sum of 3 quarters · filed 2024-08-08 | $2.79M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $697.00K 10-Q · filed 2024-05-09 | $1.39M derived: sum of 2 quarters · filed 2024-05-09 | $2.09M derived: sum of 3 quarters · filed 2024-05-09 | $2.79M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.39M derived: sum of 2 quarters · filed 2024-02-29 | $2.09M derived: sum of 3 quarters · filed 2024-02-29 | $2.79M 10-K · filed 2024-02-29 |
| 2022-09-30 | $697.00K 10-Q · filed 2023-11-09 | $1.39M derived: sum of 2 quarters · filed 2023-11-09 | $2.09M 10-Q · filed 2023-11-09 | $2.79M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $697.00K 10-Q · filed 2023-08-09 | $1.39M 10-Q · filed 2023-08-09 | $2.09M derived: sum of 3 quarters · filed 2023-08-09 | $2.79M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $697.00K 10-Q · filed 2023-05-11 | $1.39M derived: sum of 2 quarters · filed 2023-05-11 | $2.09M derived: sum of 3 quarters · filed 2023-05-11 | $2.79M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.39M derived: sum of 2 quarters · filed 2023-03-15 | $2.09M derived: sum of 3 quarters · filed 2023-03-15 | $2.63M 10-K · filed 2023-03-15 |
| 2021-09-30 | $697.00K 10-Q · filed 2022-11-08 | $1.39M derived: sum of 2 quarters · filed 2022-11-08 | $1.93M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $697.00K 10-Q · filed 2022-08-11 | $1.24M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $541.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |